The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1523
Ocrelizumab (Ocrevus) for MS
The full article is available to subscribers Subscriber Login   

The FDA has approved ocrelizumab (Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.

STANDARD TREATMENT — Most patients with MS present with the relapsing-remitting form of the disease. About 10-15% have the primary progressive form, which is characterized by worsening neurological function from the time of symptom onset.1,2

Primary Progressive MS – Drugs used for treatment of primary progressive MS have included intravenous (IV) glucocorticoids, oral or subcutaneous (SC) methotrexate, IV or SC cladribine, IV immune globulin, and IV mitoxantrone. None of these drugs are approved ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ocrelizumab (Ocrevus) for MS
Article code: 1523b
 Electronic, downloadable article - $25